NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTC: LXRP) utilizes disruptive technology for the improved delivery of bioactive compounds. A recent article discussing this reads, “Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://nnw.fm/Fq0to). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via smoking.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer